Free Trial

Relay Therapeutics (RLAY) Financials

Relay Therapeutics logo
$2.95 +0.10 (+3.51%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.90 -0.05 (-1.69%)
As of 05/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Relay Therapeutics

Annual Income Statements for Relay Therapeutics

This table shows Relay Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-338 -342 -291
Consolidated Net Income / (Loss)
-338 -342 -291
Net Income / (Loss) Continuing Operations
-338 -342 -291
Total Pre-Tax Income
-338 -342 -291
Total Operating Income
-372 -373 -299
Total Gross Profit
10 26 1.38
Total Revenue
10 26 1.38
Operating Revenue
10 26 1.38
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
382 399 301
Selling, General & Admin Expense
77 75 66
Research & Development Expense
319 330 246
Other Operating Expenses / (Income)
-13 -6.42 -12
Total Other Income / (Expense), net
35 31 8.77
Interest & Investment Income
35 31 8.79
Other Income / (Expense), net
0.01 -0.02 -0.02
Basic Earnings per Share
($2.36) ($2.79) ($2.59)
Weighted Average Basic Shares Outstanding
142.87M 122.58M 112.23M
Diluted Earnings per Share
($2.36) ($2.79) ($2.59)
Weighted Average Diluted Shares Outstanding
142.87M 122.58M 112.23M
Weighted Average Basic & Diluted Shares Outstanding
169.52M 131.18M 121.38M

Quarterly Income Statements for Relay Therapeutics

This table shows Relay Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-76 -88 -92 -81 -83 -66 -99 -94 -68 -84
Consolidated Net Income / (Loss)
-76 -88 -92 -81 -83 -66 -99 -94 -68 -84
Net Income / (Loss) Continuing Operations
-76 -88 -92 -81 -83 -66 -99 -94 -68 -84
Total Pre-Tax Income
-76 -88 -92 -81 -83 -66 -99 -94 -68 -84
Total Operating Income
-85 -96 -101 -90 -92 -74 -106 -101 -73 -86
Total Operating Expenses
85 96 101 100 92 99 106 101 73 86
Selling, General & Admin Expense
17 20 20 20 17 18 20 20 16 16
Research & Development Expense
68 77 92 82 77 81 88 83 67 67
Total Other Income / (Expense), net
8.98 8.26 8.55 8.98 8.70 7.84 7.55 6.94 5.35 1.72
Interest & Investment Income
8.97 8.27 8.55 8.95 8.70 7.85 7.56 6.94 5.37 1.71
Other Income / (Expense), net
0.00 -0.01 -0.00 0.03 0.00 -0.00 -0.01 -0.00 -0.02 0.01
Basic Earnings per Share
($0.42) ($0.63) ($0.69) ($0.62) ($0.66) ($0.54) ($0.81) ($0.78) ($0.55) ($0.76)
Weighted Average Basic Shares Outstanding
142.87M 140.23M 132.82M 130.84M 122.58M 122.23M 121.68M 121.32M 112.23M 110.91M
Diluted Earnings per Share
($0.42) ($0.63) ($0.69) ($0.62) ($0.66) ($0.54) ($0.81) ($0.78) ($0.55) ($0.76)
Weighted Average Diluted Shares Outstanding
142.87M 140.23M 132.82M 130.84M 122.58M 122.23M 121.68M 121.32M 112.23M 110.91M
Weighted Average Basic & Diluted Shares Outstanding
169.52M 167.38M 133.89M 132.74M 131.18M 123.27M 122.13M 121.61M 121.38M 120.89M

Annual Cash Flow Statements for Relay Therapeutics

This table details how cash moves in and out of Relay Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-20 -7.93 -128
Net Cash From Operating Activities
-249 -300 -229
Net Cash From Continuing Operating Activities
-249 -300 -229
Net Income / (Loss) Continuing Operations
-338 -342 -291
Consolidated Net Income / (Loss)
-338 -342 -291
Depreciation Expense
5.46 5.27 4.13
Amortization Expense
-12 -11 1.18
Non-Cash Adjustments To Reconcile Net Income
94 86 56
Changes in Operating Assets and Liabilities, net
1.41 -39 -0.43
Net Cash From Investing Activities
-41 258 -189
Net Cash From Continuing Investing Activities
-41 258 -189
Purchase of Property, Plant & Equipment
-2.02 -4.13 -9.06
Purchase of Investments
-651 -386 -535
Sale of Property, Plant & Equipment
0.00 0.00 0.00
Sale and/or Maturity of Investments
612 647 356
Net Cash From Financing Activities
270 35 290
Net Cash From Continuing Financing Activities
270 35 290
Issuance of Preferred Equity
0.00 0.00 0.00
Issuance of Common Equity
270 35 290

Quarterly Cash Flow Statements for Relay Therapeutics

This table details how cash moves in and out of Relay Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-28 18 -19 9.13 -7.59 5.43 -15 9.48 -203 247
Net Cash From Operating Activities
-58 -75 -66 -50 -89 -75 -69 -67 -57 -66
Net Cash From Continuing Operating Activities
-58 -75 -66 -50 -89 -75 -69 -67 -57 -66
Net Income / (Loss) Continuing Operations
-76 -88 -92 -81 -83 -66 -99 -94 -68 -84
Consolidated Net Income / (Loss)
-76 -88 -92 -81 -83 -66 -99 -94 -68 -84
Depreciation Expense
1.33 1.37 1.37 1.40 1.38 1.36 1.33 1.20 1.17 1.03
Amortization Expense
-2.18 -3.18 -3.29 -3.67 -3.67 -2.88 -2.20 -2.02 -0.39 0.34
Non-Cash Adjustments To Reconcile Net Income
18 22 27 27 19 22 23 22 14 14
Changes in Operating Assets and Liabilities, net
1.45 -7.65 1.47 6.15 -23 -30 7.36 6.41 -4.17 2.94
Net Cash From Investing Activities
29 -126 46 11 60 71 51 75 -147 27
Net Cash From Continuing Investing Activities
29 -126 46 11 60 71 51 75 -147 27
Purchase of Investments
-75 -265 -120 -191 -137 -85 -66 -98 -328 -56
Sale and/or Maturity of Investments
104 139 165 203 197 157 119 175 183 85
Net Cash From Financing Activities
0.80 219 1.54 49 22 9.46 2.08 1.30 1.17 286
Net Cash From Continuing Financing Activities
0.80 219 1.54 49 22 9.46 2.08 1.30 1.17 286
Issuance of Common Equity
0.80 219 1.54 49 22 9.46 2.08 1.30 2.30 286

Annual Balance Sheets for Relay Therapeutics

This table presents Relay Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
871 844 1,100
Total Current Assets
809 770 1,020
Cash & Equivalents
124 144 152
Short-Term Investments
657 606 847
Prepaid Expenses
17 17 12
Other Current Assets
11 3.32 8.17
Plant, Property, & Equipment, net
5.91 11 12
Total Noncurrent Assets
56 63 69
Intangible Assets
2.30 2.30 2.30
Other Noncurrent Operating Assets
54 61 66
Total Liabilities & Shareholders' Equity
871 844 1,100
Total Liabilities
94 92 150
Total Current Liabilities
51 30 64
Accounts Payable
14 9.21 11
Accrued Expenses
21 15 23
Current Deferred Revenue
7.68 0.00 -
Other Current Liabilities
7.72 6.17 30
Total Noncurrent Liabilities
43 62 86
Capital Lease Obligations
43 49 53
Other Noncurrent Operating Liabilities
0.00 13 32
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
778 752 950
Total Preferred & Common Equity
778 752 950
Preferred Stock
0.00 0.00 0.00
Total Common Equity
778 752 950
Common Stock
2,517 2,153 2,019
Retained Earnings
-1,738 -1,401 -1,059
Accumulated Other Comprehensive Income / (Loss)
-0.99 -0.20 -10

Quarterly Balance Sheets for Relay Therapeutics

This table presents Relay Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
930 773 841 907 962 1,038 1,169
Total Current Assets
865 704 770 832 884 958 1,087
Cash & Equivalents
152 134 153 151 146 161 355
Short-Term Investments
687 554 597 659 726 777 699
Prepaid Expenses
19 10 13 17 9.31 11 17
Other Current Assets
6.80 5.73 7.30 3.68 3.39 9.03 16
Plant, Property, & Equipment, net
7.21 8.35 9.88 11 12 12 11
Total Noncurrent Assets
58 60 61 64 66 67 70
Intangible Assets
2.30 2.30 2.30 2.30 2.30 2.30 2.30
Other Noncurrent Operating Assets
55 58 59 62 64 65 68
Total Liabilities & Shareholders' Equity
930 773 841 907 962 1,038 1,169
Total Liabilities
91 91 96 129 152 154 169
Total Current Liabilities
47 45 37 51 72 70 71
Accounts Payable
6.87 11 7.97 13 15 12 9.49
Accrued Expenses
33 28 22 31 27 28 29
Other Current Liabilities
6.89 6.10 6.81 5.89 30 31 33
Total Noncurrent Liabilities
44 46 59 78 80 84 98
Capital Lease Obligations
44 46 47 50 51 - 55
Other Noncurrent Operating Liabilities
0.00 0.00 11 28 29 84 43
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
839 682 746 778 810 883 1,000
Total Preferred & Common Equity
839 682 746 778 810 883 1,000
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
839 682 746 778 810 883 1,000
Common Stock
2,499 2,257 2,229 2,099 2,068 2,042 2,004
Retained Earnings
-1,662 -1,574 -1,482 -1,317 -1,251 -1,153 -991
Accumulated Other Comprehensive Income / (Loss)
2.51 -1.34 -1.16 -3.39 -6.08 -5.80 -13

Annual Metrics And Ratios for Relay Therapeutics

This table displays calculated financial ratios and metrics derived from Relay Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
-60.83% 1,749.82% -54.41%
EBITDA Growth
-0.21% -28.75% 18.05%
EBIT Growth
0.15% -24.63% 17.93%
NOPAT Growth
0.14% -24.63% 17.94%
Net Income Growth
1.25% -17.72% 20.16%
EPS Growth
15.41% -7.72% 32.20%
Operating Cash Flow Growth
17.05% -30.86% -208.43%
Free Cash Flow Firm Growth
18.65% -11.74% -150.04%
Invested Capital Growth
-22.16% 957.67% 107.91%
Revenue Q/Q Growth
0.01% -0.98% -18.53%
EBITDA Q/Q Growth
2.23% -6.29% -2.11%
EBIT Q/Q Growth
1.90% -5.46% -1.75%
NOPAT Q/Q Growth
1.90% -5.47% -1.74%
Net Income Q/Q Growth
2.17% -4.91% -0.02%
EPS Q/Q Growth
9.23% -4.10% 1.52%
Operating Cash Flow Q/Q Growth
11.17% -11.97% -8.19%
Free Cash Flow Firm Q/Q Growth
14.46% -15.95% -19.17%
Invested Capital Q/Q Growth
-9.86% 186.91% 726.17%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-3,790.40% -1,481.69% -21,287.69%
Operating Margin
-3,722.07% -1,460.11% -21,670.89%
EBIT Margin
-3,721.93% -1,460.18% -21,672.34%
Profit (Net Income) Margin
-3,374.72% -1,338.66% -21,036.13%
Tax Burden Percent
100.00% 100.00% 100.00%
Interest Burden Percent
90.67% 91.68% 97.06%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-581.57% -946.25% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-570.88% -936.43% 0.00%
Return on Net Nonoperating Assets (RNNOA)
537.42% 906.07% 0.00%
Return on Equity (ROE)
-44.15% -40.18% -31.44%
Cash Return on Invested Capital (CROIC)
-556.65% -1,111.70% -5,758.85%
Operating Return on Assets (OROA)
-43.43% -38.38% -28.39%
Return on Assets (ROA)
-39.38% -35.19% -27.56%
Return on Common Equity (ROCE)
-44.15% -40.18% -31.44%
Return on Equity Simple (ROE_SIMPLE)
-43.42% -45.48% -30.57%
Net Operating Profit after Tax (NOPAT)
-261 -261 -209
NOPAT Margin
-2,605.45% -1,022.08% -15,169.62%
Net Nonoperating Expense Percent (NNEP)
-10.69% -9.82% -8.51%
Return On Investment Capital (ROIC_SIMPLE)
-31.77% -32.62% -20.87%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
765.38% 293.39% 4,777.55%
R&D to Revenue
3,188.66% 1,291.86% 17,838.88%
Operating Expenses to Revenue
3,822.07% 1,560.11% 21,770.89%
Earnings before Interest and Taxes (EBIT)
-372 -373 -299
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-379 -379 -294
Valuation Ratios
- - -
Price to Book Value (P/BV)
0.89 1.80 1.90
Price to Tangible Book Value (P/TBV)
0.89 1.81 1.91
Price to Revenue (P/Rev)
68.91 53.13 1,307.87
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 13.00 180.56
Enterprise Value to Revenue (EV/Rev)
0.00 25.66 623.26
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.06 0.06 0.06
Long-Term Debt to Equity
0.06 0.06 0.06
Financial Leverage
-0.94 -0.97 -1.03
Leverage Ratio
1.12 1.14 1.14
Compound Leverage Factor
1.02 1.05 1.11
Debt to Total Capital
5.21% 6.06% 5.33%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
5.21% 6.06% 5.33%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
94.79% 93.94% 94.67%
Debt to EBITDA
-0.11 -0.13 -0.18
Net Debt to EBITDA
1.95 1.85 3.22
Long-Term Debt to EBITDA
-0.11 -0.13 -0.18
Debt to NOPAT
-0.16 -0.19 -0.26
Net Debt to NOPAT
2.83 2.69 4.51
Long-Term Debt to NOPAT
-0.16 -0.19 -0.26
Altman Z-Score
1.28 6.15 6.04
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
15.95 25.44 16.00
Quick Ratio
15.40 24.78 15.68
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-250 -307 -275
Operating Cash Flow to CapEx
-12,344.25% -7,278.62% -2,532.44%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.01 0.03 0.00
Accounts Receivable Turnover
0.00 0.00 3.90
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
1.19 2.27 0.15
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 93.69
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 93.69
Capital & Investment Metrics
- - -
Invested Capital
39 50 4.77
Invested Capital Turnover
0.22 0.93 -0.05
Increase / (Decrease) in Invested Capital
-11 46 65
Enterprise Value (EV)
-49 656 861
Market Capitalization
690 1,357 1,806
Book Value per Share
$4.65 $6.10 $7.86
Tangible Book Value per Share
$4.63 $6.08 $7.84
Total Capital
821 801 1,004
Total Debt
43 49 53
Total Long-Term Debt
43 49 53
Net Debt
-739 -702 -945
Capital Expenditures (CapEx)
2.02 4.13 9.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-23 -10 -43
Debt-free Net Working Capital (DFNWC)
758 740 956
Net Working Capital (NWC)
758 740 956
Net Nonoperating Expense (NNE)
77 81 81
Net Nonoperating Obligations (NNO)
-739 -702 -945
Total Depreciation and Amortization (D&A)
-6.85 -5.49 5.31
Debt-free, Cash-free Net Working Capital to Revenue
-228.32% -40.13% -3,122.45%
Debt-free Net Working Capital to Revenue
7,579.44% 2,896.09% 69,210.43%
Net Working Capital to Revenue
7,579.44% 2,896.09% 69,210.43%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($2.36) ($2.79) ($2.59)
Adjusted Weighted Average Basic Shares Outstanding
142.87M 122.58M 112.23M
Adjusted Diluted Earnings per Share
($2.36) ($2.79) ($2.59)
Adjusted Weighted Average Diluted Shares Outstanding
142.87M 122.58M 121.38M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
169.52M 131.18M 121.38M
Normalized Net Operating Profit after Tax (NOPAT)
-261 -261 -209
Normalized NOPAT Margin
-2,605.45% -1,022.08% -15,169.62%
Pre Tax Income Margin
-3,374.72% -1,338.66% -21,036.13%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Relay Therapeutics

This table displays calculated financial ratios and metrics derived from Relay Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% -100.00% -100.00% 4,327.88% -100.40% 7,226.16% -67.40% -46.06% -55.38% -48.35%
EBITDA Growth
9.17% -30.76% 3.97% 9.21% -31.06% 11.15% -40.16% -66.98% -9.22% -42.50%
EBIT Growth
7.83% -30.99% 5.00% 10.72% -26.51% 14.33% -36.34% -61.26% -7.61% -40.82%
NOPAT Growth
7.83% -30.98% 4.99% 10.69% -26.55% 14.34% -36.29% -61.31% -7.57% -40.83%
Net Income Growth
8.97% -34.03% 6.39% 13.64% -23.69% 21.91% -28.28% -51.89% -0.07% -38.37%
EPS Growth
36.36% -16.67% 14.81% 20.51% -20.00% 28.95% -14.08% -36.84% 6.78% -15.15%
Operating Cash Flow Growth
35.12% 0.42% 4.03% 25.04% -56.25% -13.99% -20.16% -36.52% -43.75% -24.34%
Free Cash Flow Firm Growth
56.16% -36.38% -17.38% -209.04% 5.03% 19.01% -118.39% -3,280.60% -218.29% -350.86%
Invested Capital Growth
-22.16% 147.76% 477.48% 179.63% 957.67% 2,945.58% 72.98% -52.56% 107.91% 102.42%
Revenue Q/Q Growth
0.00% 0.00% -100.00% 1,000,800.00% -100.00% 21,078.15% -47.35% -10.67% -26.45% -5.75%
EBITDA Q/Q Growth
12.59% 4.37% -10.88% 1.99% -25.83% 29.78% -4.83% -41.48% 14.69% -10.78%
EBIT Q/Q Growth
11.83% 4.35% -11.54% 2.01% -25.30% 30.63% -4.83% -38.84% 15.15% -10.40%
NOPAT Q/Q Growth
11.82% 4.36% -11.50% 1.99% -25.31% 30.62% -4.82% -38.88% 15.18% -10.39%
Net Income Q/Q Growth
13.73% 4.45% -13.30% 2.52% -27.02% 33.27% -4.53% -39.61% 19.80% -9.62%
EPS Q/Q Growth
33.33% 8.70% -11.29% 6.06% -22.22% 33.33% -3.85% -41.82% 27.63% -7.04%
Operating Cash Flow Q/Q Growth
22.93% -14.05% -30.82% 43.58% -18.29% -9.91% -2.19% -17.61% 13.71% -15.85%
Free Cash Flow Firm Q/Q Growth
48.29% 22.13% 25.46% -46.08% -60.86% 32.98% -96.24% 55.11% -37.19% -80.71%
Invested Capital Q/Q Growth
-9.86% 11.37% -9.75% -14.09% 186.91% 269.69% 80.96% -1,241.01% 726.17% 101.51%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% 0.00% 0.00% -925.43% 0.00% -297.96% -89,857.98% -45,132.74% -28,495.65% -24,567.44%
Operating Margin
0.00% 0.00% 0.00% -903.00% 0.00% -291.95% -89,117.65% -44,768.58% -28,794.86% -24,968.60%
EBIT Margin
0.00% 0.00% 0.00% -902.75% 0.00% -291.96% -89,129.41% -44,769.91% -28,804.35% -24,966.57%
Profit (Net Income) Margin
0.00% 0.00% 0.00% -813.30% 0.00% -260.83% -82,777.31% -41,698.67% -26,681.03% -24,468.60%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
89.44% 91.42% 91.52% 90.09% 90.56% 89.34% 92.87% 93.14% 92.63% 98.01%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -581.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% -579.39% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 573.47% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% 0.00% 0.00% -40.40% 0.00% -7.53% -43.33% -37.41% -31.44% -36.98%
Cash Return on Invested Capital (CROIC)
-556.65% -954.80% -765.56% -810.89% -1,111.70% -2,915.20% 0.00% 0.00% -5,758.85% -39,922.86%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% -33.95% 0.00% -7.26% -90.70% -53.52% -37.74% -45.99%
Return on Assets (ROA)
0.00% 0.00% 0.00% -30.58% 0.00% -6.48% -84.23% -49.85% -34.96% -45.07%
Return on Common Equity (ROCE)
0.00% 0.00% 0.00% -40.40% 0.00% -7.53% -43.33% -37.41% -31.44% -36.98%
Return on Equity Simple (ROE_SIMPLE)
0.00% -41.15% -47.35% -44.13% 0.00% -41.88% -42.51% -36.53% 0.00% -29.05%
Net Operating Profit after Tax (NOPAT)
-59 -67 -71 -63 -65 -52 -74 -71 -51 -60
NOPAT Margin
0.00% 0.00% 0.00% -632.10% 0.00% -204.36% -62,382.35% -31,338.01% -20,156.40% -17,478.02%
Net Nonoperating Expense Percent (NNEP)
-2.29% -2.65% -2.96% -2.21% -2.30% -1.62% -2.96% -2.58% -1.73% -3.02%
Return On Investment Capital (ROIC_SIMPLE)
-7.25% - - - -8.06% - - - -5.08% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 197.85% 0.00% 73.35% 16,907.56% 8,663.27% 6,470.75% 4,672.67%
R&D to Revenue
0.00% 0.00% 0.00% 823.45% 0.00% 323.36% 74,118.49% 36,649.12% 26,591.70% 19,447.67%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 1,003.00% 0.00% 391.95% 89,217.65% 44,868.58% 28,894.86% 25,068.60%
Earnings before Interest and Taxes (EBIT)
-85 -96 -101 -90 -92 -74 -106 -101 -73 -86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-86 -98 -103 -93 -94 -75 -107 -102 -72 -85
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.89 1.13 1.27 1.37 1.80 1.32 1.89 2.26 1.90 2.44
Price to Tangible Book Value (P/TBV)
0.89 1.13 1.27 1.38 1.81 1.32 1.89 2.27 1.91 2.44
Price to Revenue (P/Rev)
68.91 94.74 24.58 28.96 53.13 39.81 1,621.51 1,682.83 1,307.87 1,437.20
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 3.51 5.70 7.40 13.00 15.16 0.00 0.00 180.56 2,490.22
Enterprise Value to Revenue (EV/Rev)
0.00 15.25 6.33 9.08 25.66 10.32 750.52 893.44 623.26 847.70
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.06 0.05 0.07 0.06 0.06 0.06 0.06 0.00 0.06 0.05
Long-Term Debt to Equity
0.06 0.05 0.07 0.06 0.06 0.06 0.06 0.00 0.06 0.05
Financial Leverage
-0.94 -0.96 -0.98 -1.01 -0.97 -0.99 -1.03 -1.05 -1.03 -1.01
Leverage Ratio
1.12 1.14 1.16 1.15 1.14 1.17 1.16 1.15 1.14 1.17
Compound Leverage Factor
1.00 1.04 1.06 1.04 1.03 1.04 1.08 1.07 1.06 1.15
Debt to Total Capital
5.21% 5.01% 6.29% 5.95% 6.06% 6.01% 5.93% 0.00% 5.33% 5.18%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
5.21% 5.01% 6.29% 5.95% 6.06% 6.01% 5.93% 0.00% 5.33% 5.18%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
94.79% 94.99% 93.71% 94.05% 93.94% 93.99% 94.07% 100.00% 94.67% 94.82%
Debt to EBITDA
-0.11 -0.11 -0.13 -0.13 -0.13 -0.14 -0.14 0.00 -0.18 -0.19
Net Debt to EBITDA
1.95 2.05 1.76 1.90 1.85 2.14 2.24 0.00 3.22 3.47
Long-Term Debt to EBITDA
-0.11 -0.11 -0.13 -0.13 -0.13 -0.14 -0.14 0.00 -0.18 -0.19
Debt to NOPAT
-0.16 -0.17 -0.18 -0.19 -0.19 -0.20 -0.20 0.00 -0.26 -0.27
Net Debt to NOPAT
2.83 2.99 2.57 2.77 2.69 3.07 3.20 0.00 4.51 4.85
Long-Term Debt to NOPAT
-0.16 -0.17 -0.18 -0.19 -0.19 -0.20 -0.20 0.00 -0.26 -0.27
Altman Z-Score
2.37 4.46 3.51 4.68 7.25 3.55 4.86 6.93 6.72 8.27
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
15.95 18.42 15.64 20.73 25.44 16.39 12.36 13.60 16.00 15.22
Quick Ratio
15.40 17.88 15.28 20.18 24.78 15.98 12.18 13.31 15.68 14.76
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-48 -93 -120 -161 -110 -68 -102 -52 -116 -85
Operating Cash Flow to CapEx
0.00% -33,076.21% -598,481.82% -2,827.13% -75,583.05% -12,779.15% -4,564.27% -3,505.48% -2,464.55% -3,157.28%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.01 0.01 0.04 0.04 0.03 0.02 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 114.16 5.15 4.28 3.90 3.24
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
1.19 1.12 3.50 3.24 2.27 2.34 0.09 0.11 0.15 0.19
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 3.20 70.91 85.26 93.69 112.51
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 3.20 70.91 85.26 93.69 112.51
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
39 44 39 43 50 18 -10 -54 4.77 0.58
Invested Capital Turnover
0.22 0.33 2.45 -6.38 0.93 2.84 -0.04 -0.03 -0.05 -0.15
Increase / (Decrease) in Invested Capital
-11 26 49 98 46 17 28 -19 65 24
Enterprise Value (EV)
-49 153 223 321 656 266 707 1,061 861 1,437
Market Capitalization
690 948 865 1,023 1,357 1,027 1,527 1,999 1,806 2,436
Book Value per Share
$4.65 $6.27 $5.14 $5.70 $6.10 $6.37 $6.66 $7.28 $7.86 $9.18
Tangible Book Value per Share
$4.63 $6.25 $5.12 $5.68 $6.08 $6.35 $6.64 $7.26 $7.84 $9.16
Total Capital
821 883 728 793 801 828 861 883 1,004 1,054
Total Debt
43 44 46 47 49 50 51 0.00 53 55
Total Long-Term Debt
43 44 46 47 49 50 51 0.00 53 55
Net Debt
-739 -795 -643 -702 -702 -761 -820 -938 -945 -999
Capital Expenditures (CapEx)
0.00 0.23 0.01 1.78 0.12 0.59 1.50 1.92 2.32 2.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-23 -21 -29 -17 -10 -30 -59 -50 -43 -38
Debt-free Net Working Capital (DFNWC)
758 818 659 733 740 781 813 888 956 1,016
Net Working Capital (NWC)
758 818 659 733 740 781 813 888 956 1,016
Net Nonoperating Expense (NNE)
17 21 22 18 19 14 24 23 17 24
Net Nonoperating Obligations (NNO)
-739 -795 -643 -702 -702 -761 -820 -938 -945 -999
Total Depreciation and Amortization (D&A)
-0.85 -1.81 -1.92 -2.27 -2.29 -1.51 -0.87 -0.82 0.78 1.37
Debt-free, Cash-free Net Working Capital to Revenue
-228.32% -214.35% -82.90% -47.14% -40.13% -114.59% -6,242.04% -4,198.91% -3,122.45% -2,237.29%
Debt-free Net Working Capital to Revenue
7,579.44% 8,176.70% 1,872.38% 2,074.78% 2,896.09% 3,027.33% 86,281.63% 74,740.82% 69,210.43% 59,933.33%
Net Working Capital to Revenue
7,579.44% 8,176.70% 1,872.38% 2,074.78% 2,896.09% 3,027.33% 86,281.63% 74,740.82% 69,210.43% 59,933.33%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.42) ($0.63) ($0.69) ($0.62) ($0.66) ($0.54) ($0.81) ($0.78) ($0.55) ($0.76)
Adjusted Weighted Average Basic Shares Outstanding
142.87M 140.23M 132.82M 130.84M 122.58M 122.23M 121.68M 121.32M 112.23M 110.91M
Adjusted Diluted Earnings per Share
($0.42) ($0.63) ($0.69) ($0.62) ($0.66) ($0.54) ($0.81) ($0.78) ($0.55) ($0.76)
Adjusted Weighted Average Diluted Shares Outstanding
142.87M 140.23M 132.82M 130.84M 122.58M 122.23M 121.68M 121.32M 112.23M 110.91M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
169.52M 167.38M 133.89M 132.74M 131.18M 123.27M 122.13M 121.61M 121.38M 120.89M
Normalized Net Operating Profit after Tax (NOPAT)
-59 -67 -71 -63 -65 -52 -74 -71 -51 -60
Normalized NOPAT Margin
0.00% 0.00% 0.00% -632.10% 0.00% -204.36% -62,382.35% -31,338.01% -20,156.40% -17,478.02%
Pre Tax Income Margin
0.00% 0.00% 0.00% -813.30% 0.00% -260.83% -82,777.31% -41,698.67% -26,681.03% -24,468.60%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Relay Therapeutics' Financials

When does Relay Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Relay Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Relay Therapeutics' net income changed over the last 2 years?

Relay Therapeutics' net income appears to be on an upward trend, with a most recent value of -$337.71 million in 2024, rising from -$290.51 million in 2022. The previous period was -$341.97 million in 2023. Find out what analysts predict for Relay Therapeutics in the coming months.

What is Relay Therapeutics's operating income?
Relay Therapeutics's total operating income in 2024 was -$372.47 million, based on the following breakdown:
  • Total Gross Profit: $10.01 million
  • Total Operating Expenses: $382.48 million
How has Relay Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Relay Therapeutics' total revenue changed from $1.38 million in 2022 to $10.01 million in 2024, a change of 624.6%.

How much debt does Relay Therapeutics have?

Relay Therapeutics' total liabilities were at $93.50 million at the end of 2024, a 1.7% increase from 2023, and a 37.5% decrease since 2022.

How much cash does Relay Therapeutics have?

In the past 2 years, Relay Therapeutics' cash and equivalents has ranged from $124.29 million in 2024 to $151.79 million in 2022, and is currently $124.29 million as of their latest financial filing in 2024.

How has Relay Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Relay Therapeutics' book value per share changed from 7.86 in 2022 to 4.65 in 2024, a change of -40.9%.



This page (NASDAQ:RLAY) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners